企業概要
Eton Pharmaceuticals, Inc. is a pharmaceutical entity dedicated to the research, development, and commercialization of therapeutic solutions specifically targeting rare diseases. The company operates within the Healthcare sector, more precisely categorized under the industry of Drug Manufacturers - Specialty & Generic, a classification that signifies its focus on niche therapeutic areas requiring specialized formulation and regulatory expertise. As of the latest data, the enterprise maintains a market capitalization of $739.41M, generated annual revenue of $79.95M, and employs a workforce of 44 individuals. These valuation and revenue metrics position Eton as a mid-cap specialty manufacturer, indicating a firm that has achieved significant scale in a fragmented market but remains sensitive to the commercialization cycles of its specific rare disease portfolios.
財務健全性
The company reported total revenue of $79.95M over the trailing twelve months, accompanied by a net income loss of $-4,601,000 and an EBITDA of $8.88M. The substantial disparity between the positive EBITDA of $8.88M and the negative net income of $-4,601,000 reveals a cost structure characterized by significant non-operating expenses, likely comprising interest charges or other financial costs that erode bottom-line profitability despite operational cash generation. This financial dynamic highlights a leverage-heavy capital structure where operating earnings are not sufficient to cover debt obligations without creating a net loss. Despite the reported net loss, the firm generated positive free cash flow of $11.16M, which indicates a degree of financial flexibility allowing for operational reinvestment or debt servicing without relying on external equity financing. The company holds $25.94M in cash assets against total debt of $31.08M, resulting in a debt-to-equity ratio of 118.85, which suggests a highly leveraged balance sheet where liabilities significantly exceed equity. Liquidity is supported by a current ratio of 1.57, indicating that current assets are sufficient to cover short-term obligations with a buffer of 57% above the required level. Return on Equity stands at -18.2% while Return on Assets is 3.6%, metrics that collectively reveal that management effectiveness in generating shareholder value is currently hampered by the net loss, even though asset utilization remains positive.
バリュエーション評価
Valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to the net loss, while the Forward P/E is calculated at 17.37. The absence of a trailing P/E and the presence of a forward multiple imply that the market is pricing in an anticipated future earnings trajectory that is expected to turn positive, suggesting a turnaround expectation rather than current profitability. The price-to-book ratio is elevated at 28.02, indicating that the stock trades at a significant premium relative to its tangible book value, a common characteristic for companies in the specialty drug sector where intangible assets like intellectual property drive value. Alternative valuation measures include a price-to-sales ratio of 9.25 and an EV/EBITDA of 83.89, which suggests the market values the company based on future revenue potential and normalized earnings power rather than current cash flows. Regarding price volatility, the 52-week high is $27.19 and the 52-week low is $11.09, providing a historical trading range for reference. The current price metrics indicate the stock is trading at approximately 84% below the 52-week high, reflecting significant price compression over the last year. The stock exhibits a beta of 0.97, meaning its price volatility closely mirrors that of the broader market, implying it does not systematically outperform or underperform the market index during periods of general fluctuation.
Growth & Income
Revenue growth over the last year has accelerated to 82.7%, demonstrating a robust expansion in sales volume or pricing power, whereas earnings growth is N/A due to the current net loss status. This divergence implies that while top-line expansion is occurring rapidly, the company has not yet achieved profitability, meaning earnings are growing slower than revenue or are currently negative. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings and reinvests capital back into the business to fund its rare disease development programs and commercialization efforts. The overall growth and income profile is defined by high revenue expansion and zero dividend distribution, prioritizing capital allocation toward organic growth initiatives rather than shareholder returns.